Related Experiment Videos
Dipyridamole and thrombocyte count in open-heart surgery
The Journal of Thoracic and Cardiovascular Surgery
|October 1, 1975
Summary
Dipyridamole (Persantine) helps maintain thrombocyte (platelet) counts during open-heart surgery. This study found dipyridamole use did not increase bleeding, supporting its potential benefit in cardiac surgery patients.
Area of Science:
- Cardiology
- Hematology
Background:
- Thrombocytopenia is a common complication during cardiopulmonary bypass.
- Maintaining adequate platelet counts is crucial for hemostasis during cardiac surgery.
Purpose of the Study:
- To evaluate the effect of dipyridamole on thrombocyte counts in patients undergoing open-heart surgery.
- To assess the safety of dipyridamole regarding postoperative bleeding.
Main Methods:
- A prospective study involving 12 patients receiving intravenous dipyridamole (40-80 mg).
- A control group of 38 patients undergoing open-heart surgery without dipyridamole.
- Thrombocyte counts were measured at the end of anesthesia and perfusion.
Main Results:
- Dipyridamole administration resulted in significantly higher mean thrombocyte counts post-perfusion (129 x 10(9)/L vs. 82 x 10(9)/L) and post-anesthesia (164.9 x 10(9)/L vs. 110.8 x 10(9)/L).
- The observed differences in thrombocyte counts were statistically significant (p < 0.05).
- No increase in postoperative hemorrhagic tendency was noted in the dipyridamole group.
Conclusions:
- Dipyridamole effectively maintains thrombocyte counts during open-heart surgery.
- Dipyridamole appears to be safe for use in this context, without increasing bleeding risk.
- Findings support previous experimental data on dipyridamole's thrombocyte-sparing effects.